Tech Company Financing Transactions
NanoVation Therapeutics Funding Round
Convergent Ventures and private investors invested in a venture round for NanoVation Therapeutics. The round closed on 11/20/2024.
Transaction Overview
Company Name
Announced On
11/20/2024
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Convergent Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to support the further advancement of its lipid nanoparticle (LNP) technology platform for RNA delivery to cells outside of the liver, including the completion of large animal studies.
Company Information
Company Status
Private & Independent
Industry
Software
Mailing Address
4th Floor, 2405 Wesbrook Mall
Vancouver, BC, V6T 1Z3
Canada
Vancouver, BC, V6T 1Z3
Canada
Phone
Undisclosed
Website
Email Address
Overview
Built by world-leading experts. Driven by key opinion leaders. Enabled by local talent. At NanoVation Therapeutics�, we push the boundaries of science to make a healthier world. We work as a team to improve people's lives and realize our full workplace potential. Our team's expertise spans mRNA synthesis and LNP formulation, through to preclinical trials and delivery optimization.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dominik Witzigmann
Browse more venture capital transactions:
Prev: 11/20/2024: Cortechs.ai venture capital transaction
Next: 11/20/2024: NYSHEX venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs